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Background: Electronic nicotine delivery systems (ENDS) present an emerging issue for tobacco control and data
on product use behaviors are limited.
Methods: Participants (N = 38 enrolled; N = 16 compliant) completed three lab visits over 5 days and were asked to
abstain from regular cigarettes for 72 hours in favor of ENDS (Smoke 51 TRIO – 3 piece, First Generation with 11 mg/ml
filters). Lab visits included measurement of exhaled carbon monoxide (CO) and salivary cotinine concentration,
questionnaire measures of regular cigarette craving after the 72 hour abstinence, and subjective product effects.
Participants used a topography device to record puff volume, duration, flow rate, and inter-puff interval.
Results: Analyses revealed significant differences across products in puff count, average volume, total volume and
inter-puff interval, with ENDS broadly showing a more intensive smoking pattern. Cigarette craving scores dropped
significantly after smoking regular cigarettes, but not ENDS (p = .001), and subjective measures showed ENDS
rated less favorably. CO boost, after ENDS use, decreased significantly (p < .001), and saliva cotinine significantly
dropped between visits 1 and 3 (p < 0.001) after ENDS use relative to after cigarette smoking. For compliant and
non-compliant participants, there was an average 82.0% [V1 - 16.1 cpd; V3 - 2.9 cpd] and average 73.9% [V1 - 20.3 cpd;
V3 - 5.3 cpd] reduction in regular cigarette use per day during the ENDS trial period, respectively.
Conclusions: The ENDS were smoked more intensively than own brand cigarettes, but delivered significantly less
nicotineand were less satisfying. These findings have implications for the viability of certain ENDS as alternatives
to cigarettes.
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Electronic nicotine delivery systems (ENDS, commonly
called ‘e-cigarettes’), nicotine-containing devices contain-
ing no tobacco, represent an emergent issue in tobacco
control. A typical electronic cigarette consists of a cart-
ridge containing nicotine dissolved in propylene glycol
and/or glycerine, an atomizer, and a mouthpiece. When
the user draws on the mouthpiece, a sensor detects the
change in pressure and causes the atomizer to heat up and
vaporize a solution of nicotine and propylene glycol and/
or glycerine, which the user then inhales [1]. ENDS car-
tridges are sold with varying nicotine levels, and a number* Correspondence: Richard.OConnor@RoswellPark.org
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unless otherwise stated.of websites sell e-liquids that allow users to refill their own
cartridges or tanks [2,3].
Currently, ENDS are known to produce trace amounts
of various toxic compounds such as tobacco specific ni-
trosamines, diethylene glycol, and aldehydes (formalde-
hyde, acetaldehyde and acrolein); though levels are far
less than those in cigarettes [4-6]. Although design as-
pects of ENDS vary, leaky fluid contained in cartridge
reservoirs, poor cartridge labeling, safety features that do
not always function properly, and insufficient warnings
on packaging have been noted as reasons for concern re-
garding consumer usage [2]. Tested ENDSs require sig-
nificant vacuum pressure to aerosolize the solution in
the cartridge, which is hypothesized to lead users to in-
hale harder and deeper to obtain the vapor from theirLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Study design
STUDY DAY 1 2 3 4 5
LAB VISIT 1 2 3
Lab smoking – tobacco cigarette X
Lab smoking – ENDS X X
Field smoking – tobacco cigarette X
Field smoking – ENDS X X X
Breath X X X
Saliva X X
Urine X X
Questionnaires X X X
QSU (pre and post product use) X X X
CES (post product use only) X X X
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with a consistent density, ENDS vapor has been shown
to decrease in density after the first 10 puffs on certain
models, which also could lead users to modify their
smoking behaviors to obtain more vapor [3].
Puffing topography data are needed to confirm that the
vacuum pressure observation by Trtchounian and col-
leagues has relevance to consumer use. In a recent study
by Hua et al. [7], puff and exhalation duration were com-
pared for individuals using first generation ENDS and
conventional cigarettes in YouTube videos. They found
that puff duration was significantly longer for ENDS users
(mean = 4.3 s) (N = 64) than for conventional cigarette
users, and puff duration varied significantly among ENDS
brands. Additionally, Goniewicz et al. [8], recruited 10 vol-
unteers (aged 35 ± 20 years, 8 males) who used various
brands and models of first generation ENDS for at least
one month and measured their puffing topography. The
average puffing topography were as follows (M ± SD): puff
duration of 1.8 ± 0.9 s, intervals between puffs of 10 ± 13 s,
puff volume 70 ± 68 ml, and number of puffs taken in one
puffing session was 15 ± 6.
However, there is potential for ENDS to serve as a
long-term alternative to cigarettes and even as a smok-
ing cessation aid. Adkison et al. [9] examined data from
the International Tobacco Control Four Country Survey,
collected in 2010–11 among 5,939 current and former
smokers in Canada, the US, the UK, and Australia, and
found that among the 2.9% of the sample who currently
used ENDS, 75.4% stated that they used ENDS to help
cut down, and 85.1% used ENDS to help quit smoking. A
study in Italy revealed ENDS use substantially decreased
cigarette consumption without causing significant side ef-
fects among a group of smokers not intending to quit [10].
Additionally, Goniewicz et al. [11] reported that 41% of
ENDS users utilized ENDS to quit smoking or reduce the
harm associated with smoking. More recently, Caponnetto
et al. [12] conducted a 9 visit, 12-month, randomized, con-
trolled trial that evaluated smoking reduction/abstinence in
300 smokers (3 groups) not intending to quit; experiment-
ing two different nicotine strengths of a popular e-cigarette
model compared to its non-nicotine choice. In all three
groups, smokers not intending to quit used of e-cigarettes
to decrease cigarette consumption without significant side
effects. In a separate study, the 16 mg Ruyan ENDS allevi-
ated desire to smoke after overnight abstinence [13].
The current pilot study was initiated to examine initial
reactions to use and puffing behaviors with first gener-
ation ENDS among inexperienced users.
Methods
Participants
Participants (N = 38) were recruited from February 2011-
May 2012 via advertising in local newspapers (advertisingdid not mention the study focused on ENDS). Eligible par-
ticipants were a minimum of 18 years of age, smoked at
least 10 cigarettes daily, were not concurrently using other
tobacco or nicotine products, had no use of ENDS in the
last 30 days, reported no intention of quitting smoking
within the next 30 days, had no medical contraindications
for nicotine replacement products, were in good general
health, and had no known sensitivity to propylene glycol
and/or glycerin. Females who reported they might be
pregnant or planned to become pregnant during the study
were excluded from participation. We selected those who
had not used ENDS in the past 30 days because we were
primarily interested in initial reactions to the product
among triers, rather than experienced ENDS users.
Study design & procedures
The study design is illustrated in Table 1. Participants were
asked to visit the laboratory on 3 separate occasions (Days
1, 2, and 5) over 5 days at consistent times of the day.
Upon arrival for the first visit (Day 1), participants were
requested to complete a series of questions on tobacco use
history and awareness of ENDS as well as the Question-
naire on Smoking Urges (QSU) [14]. Participants provided
a saliva specimen, a spot urine specimen, and an exhaled
breath sample for carbon monoxide (CO) testing. Partici-
pants then smoked one of their own cigarettes using the
portable CReSS device (Borgwaldt-KC, Richmond, VA).
This same device was used by the participant for the re-
mainder of the study. Ten minutes after smoking was
completed, participants completed the Cigarette Evalu-
ation Scale (CES) [15], the QSU (post cig use), and pro-
vided a second CO sample. Upon departure, participants
were asked to take a CReSS device home and smoke any
five of their own cigarettes through the device over the
next 24 hours.
Participants returned for their 2nd visit and completed
the QSU as well as a brief questionnaire about their ex-
perience with the CReSS device. They then received a
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with a written instruction sheet. A baseline CO reading
was obtained and participants were asked to use the
ENDS via the CReSS. Neither saliva nor urine samples
were collected during the 2nd visit. The remainder of
the procedures paralleled Visit 1. Participants were
instructed to use the ENDS ONLY (no cigarettes) for the
next 72 hours, ending at their 3rd lab visit. They were
also instructed to smoke the ENDS through the CReSS
device at least 5 times per day over the following 72
hours. Participants were provided a CReSS device, an
ENDS, 3 refill cartridges, and instructions to replace the
cartridge after about 300 puffs or 24 hours. Participants
were also given a product tally sheet to track their prod-
uct use accurately and a separate form to track their
CReSS usage. Participants were instructed to return all
study materials including the CReSS device, ENDS unit,
and all used and unused cartridges to the laboratory.
Participants arrived 72 hours later for Visit 3 (Day 5),
completed the QSU, and were evaluated for compliance
with the protocol (no cigarette smoking, defined as CO <
8 ppm per Society for Research on Nicotine and Tobacco
(SRNT, 2002). Participants (N = 14) who showed CO ≥8
ppm were reimbursed for their time and excused from the
study. Compliant participants completed a brief question-
naire about their experience with the ENDS and the
CReSS device. Then, the same biospecimen (saliva and
urine) and data collection procedures as Visit 1 were
conducted.
This study protocol was reviewed and approved by the
Roswell Park Cancer Institute Institutional Review Board.
Upon review of a detailed consent form, all participants
provided their written informed consent. Participants re-
ceived a maximum of $50 for completing the study.
Measures
The CReSSmicro® (Plowshare/Borgwaldt-KC, Richmond
VA) was used to record smoking topography and has been
shown to provide valid, objective measures of smoking
topography [16,17]. A specialized adapter for the ENDS
was obtained from Borgwaldt-KC and used in this study.
CReSSMicro units were separately calibrated for tobacco
cigarettes and ENDS, and dedicated units were used for
each product. Topography measures included puff num-
ber, puff volume (ml), puff duration (msec), average flow
(ml/sec), inter-puff interval (msec), and time and date of
smoking. For reporting purposes, duration and inter-puff
interval were converted from milliseconds to seconds. We
derived total puff volume by summing puff volumes for
each cigarette/ENDS.
Saliva specimens were collected using Salivette tubes, and
assayed for cotinine using the ELISA method at Salimetrics
LLC or at RPCI. Alveolar CO was measured using a Micro
4 Smokerlyzer (Bedfont, Kent, UK). Participants wereinstructed to hold their breath for 15 seconds before pro-
viding a sample of exhaled air. After smoking or ENDS use,
10 minutes elapsed before the next CO reading was taken.
CO boost was calculated by subtracting the first reading
from the second. Urine specimens were aliquoted and fro-
zen for later analysis.
Products
The ‘cigarette-like’ “Smoke 51 TRIO” ENDS - 3 piece,
First Generation with 11 mg/ml cartridges (Vapor Corp,
Miami, FL) was tested in this study, as during the study
period it was sold in local shopping mall kiosks. All par-
ticipants used 11 mg nicotine cartridges with flavor
(tobacco, menthol) matched to that of their usual
cigarette brand; this concentration was chosen as it was
the midpoint of the range offered for this brand at the
time. Instructions on ENDS use and proper charging
were also provided verbally during the lab session and in
writing for participant home reference. The regular ciga-
rettes were the usual brand of the participant and were
not provided as part of the study protocol.
Data analysis
Participant demographics and characteristics were eval-
uated using basic descriptive analysis. QSU, CES, Top-
ography, and CO differences were all assessed using
multivariate repeated measures analysis of variance
(ANOVA). Saliva cotinine was analyzed using paired
samples t-tests. Log transformations were applied to
time to first cigarette and cotinine prior to analysis.
Statistical significance was accepted at p < .05, two
tailed. Statistical analyses were performed using SPSS
version 21 (IBM, Armonk, NY).
Results
Participant characteristics
Figure 1 is a flowchart of the study from recruitment to
final visit. Table 2 shows the demographic layout of the
study participants. A total of 38 participants initiated the
study with 21.1% (n = 8) being lost to follow-up. Even
though 78.9% (n = 30) completed the study, only 42.1%
(n = 16) of these 30 completers were actually compliant
(CO ≤ 8 ppm) based on study guidelines.
ENDS knowledge and beliefs
At baseline, all participants (N = 38) reported they were
aware of ENDS. Of these, 29% had ever tried ENDS. The
extent of prior experience, outside of use within the past
30-days, was not assessed. Eighty-two percent (N = 31) be-
lieved ENDS to be less harmful than regular cigarettes.
Product usage
At baseline, prior to study commencement, partici-
pants reported smoking an average of 17.5 (SD 7.8;
Figure 1 Flowchart of study participation.
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72-hour field trial, participants were asked to abstain
from regular cigarette use and a criterion of CO < = 8
ppm determined compliance. For compliant and non-
compliant participants, there was an average 82.0%
[V1 - 16.1 cpd; V3 - 2.9 cpd] and average 73.9% [V1 -
20.3 cpd; V3 - 5.3 cpd] reduction in regular cigarette
use per day during the ENDS trial period, respectively.Table 2 Demographic characteristics of study participants (N
Variable Lost to follow










Cigarettes per day Mean 15.4
(SE) (2.6)
Minutes to first cigarette after waking Geo. Mean 15.9
Baseline cotinine Geo. Mean 252.6
*Chi-square test for categorical variables; one-way ANOVA for continuous variables.Out of those, 2 compliant participants reported no
cigarette use at all during the 72-hour period.
Subjective measures (QSU, CES)
In the laboratory sessions, the observed drop in both
QSU Factor 1 & Factor 2 cigarette craving scores (pre-
post smoking, n = 32) was statistically significantly
greater when smoking own brand cigarettes (Figure 2),= 38)
-up
(n = 8)
Completed study (n = 30) p*














Figure 2 Mean values of questionnaire of smoking urges factor 1 (a) and factor 2 (b) before and after smoking cigarettes and
using ENDS.
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p = .001]. Indeed, on neither QSU scale did the ini-
tial ENDS trial show a significant reduction after use
(p’s > .57). Models including gender and age did not
show a substantially different pattern of findingsand
interaction terms with product and/or time were not
statistically significant.
Several measures on the Cigarette Evaluation Scale
(CES) showed significant differences between cigarettes
and ENDS (Figure 3) (n = 32) including satisfaction [F
(1,31) = 20.94, p < .001], taste good [F = 4.54, p = .04], diz-
ziness [F = 28.07, p < .001], feeling more awake [F = 12.40,
p = .001], reduced hunger for food [F = 22.51, p < .001],
increased nausea [F = 10.92, p = .002], feeling less irritable
[F = 13.65, p = .001], and reduced craving to smoke ciga-
rettes [F = 28.79, p < .001]. In each case, cigarettes showed
significantly higher scores than ENDS. In a separate model,
we examined product by age and product by genderinteractions. Only two significant effects emerged – women
rated cigarettes and ENDS similarly on enjoyment of airway
sensation (3.0 vs. 3.4) while men rated cigarettes more
highly (4.1 vs. 2.3) [F (1,29) = 8.33, p = .007]. A similar pat-
tern was seen for women (3.8 vs. 3.7) and men (4.4 vs. 2.6)
on the ‘taste good’ measure [F = 5.87, p = .02]. The QSU
and CES measures were also taken during Visit 3, but due
to the low number of completed and compliant partici-
pants, are not reported.
Puffing topography
Equipment failures led to the loss of cigarette topog-
raphy data on 6 participants and ENDS topography data
on 9 participants. A total of 3 participants were missing
both. Table 3 shows average puffing topography values
by product for both initial laboratory smoking sessions;
this includes smoking usual cigarettes and initial experi-
mental ENDS use (n = 18). Overall, when assessed at the
Figure 3 Mean values for cigarette evaluation scale items after smoking cigarettes and using ENDS.
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puff counts on cigarettes compared to initial use of
ENDS. However, per-puff volume, puff velocity, and
peak velocity were significantly higher for experimental
ENDS use. We saw no significant differences in puff
duration, interval, or total volume drawn. Interactions of
product with age and sex were again tested; none
emerged as statistically significant.
CO and nicotine exposure
Among all participants at baseline, mean exhaled CO
was 14.2 ppm (SD = 9.8). Repeated measures ANOVA of
exhaled CO (n = 33) showed a significant interaction of
product by time [F(1,32) = 84.2, p < .001]. When smok-
ing cigarettes in the laboratory, mean exhaled CO in-
creased from 15.1 ppm (SE 1.7) before smoking to
19.2 ppm (SE 1.9) after smoking. When using ENDS inTable 3 Smoking topography mean values for cigarettes
and ENDS at the laboratory session
Cigarette ENDS ANOVA
Mean SE Mean SE F (1,17) p
Puff count (n) 13.2 1.1 8.7 1.6 7.35 0.015
Per-puff volume (ml) 67.5 6.3 118.2 13.3 10.22 0.005
Puff velocity (ml/sec) 36.1 1.8 52.0 4.7 8.00 0.012
Peak velocity (ml/sec) 56.3 4.2 73.4 6.6 4.50 0.049
Duration (sec) 3.0 1.0 3.0 0.8 0.003 0.960
Inter-puff interval (sec) 21.3 6.2 29.6 11.7 0.36 0.555
Total volume (ml) 829.0 51.4 1120.7 320.8 0.84 0.373the laboratory, mean exhaled CO actually declined from
16.4 ppm (SE 2.0) before use to 14.5 ppm (SE 1.9) after
use. Analyses controlling for age and gender revealed
no statistically significant interactions.
Among all participants at baseline, saliva cotinine had
a geometric mean of 344.7 ng/mL; follow up cotinine
assessments were made only among those compliant
with the protocol (i.e., CO < = 8 ppm at Visit 3). Among
compliant participants (N = 16), geometric mean saliva
cotinine showed a significant drop between visits 1
(338.0 ng/mL) and 3 (178.4 ng/mL) [t(15) = 4.37, p < .001].
Analyses controlling for age and gender revealed no statis-
tically significant effects.
Discussion
ENDS are an emerging issue in tobacco control and an
evidence base is needed to determine their public health
impact. In this small-scale study of brief and initial experi-
ence with ENDS, we saw that ENDS use was associated
with a decrease in regular cigarettes per day in about half
the participants. This effect is not unexpected, as partici-
pants had been instructed to stop smoking entirely; how-
ever, only 2 participants actually reported smoking no
cigarettes during the 72 hour study period. Most, though,
reported decreasing their typical cigarette consumption.
Since CO boosts after using ENDS were essentially zero
and cotinine levels decreased between Visits 1 and 3
(among compliant participants), the ENDS do not appear
to deliver CO (logical as there is no combustion) and ap-
pear to deliver less nicotine than cigarettes. The nicotine
delivery finding based on cotinine is corroborated by lack
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(e.g., dizziness, nausea, cigarette craving reduction).
Studies examining nicotine delivery show that first-
generation ENDS (such as those studied here) were not
very effective at increasing the plasma nicotine concen-
tration levels in naïve research participants relative to
cigarettes [18,19]. Under acute testing conditions, while
the tested ENDS did not expose users to substantial
levels of nicotine or CO, they did suppress nicotine/to-
bacco abstinence symptom ratings [20]. In a randomized
cross-over design study by Farsalinos et al. [21] with 45
experienced ENDS users and 35 smokers, video recorded
when using the device, showed that a 20 mg/mL nicotine
concentration liquid would be needed in order to deliver
nicotine at amounts similar to a tobacco cigarette.
Since most participants were inexperienced using the
device for the first time in the laboratory, cigarettes and
ENDS also showed distinct smoking patterns; smokers
took larger, albeit fewer, puffs of higher velocity on the
ENDS. Flow rates (both average and peak) were higher on
ENDS compared to cigarettes, paralleling a recent study
that showed the airflow rate required to generate aerosol
across ENDS was higher than required for tobacco ciga-
rettes [22]. Even though 30% of participants had tried
ENDS before, there were no significant topography differ-
ences between those who had tried ENDS before and
those who had not.
A key issue in assessing the viability of alternatives to
cigarettes is consumer perception. A number of studies re-
vealed strong consumer demand for products claiming or
implying to reduce health risks [23-27]. Despite this de-
mand, consumers have often rejected such products due
to poor taste [28,29]. Sensory characteristics are an im-
portant part of cigarette design and replicating these may
increase acceptability [30,31]. In the current study, it was
clear that smokers did not have equivalent experiences
with cigarettes and ENDS. ENDS were rated less positively
in taste, satisfaction, and reducing hunger and irritability.
Unlike cigarette smoking, we saw no evidence for ENDS
reducing cigarette cravings in the laboratory. This was
replicated across the two subscales of the QSU and a sin-
gle item on cigarette craving reduction in the CES. Taken
together, this suggests that the product used in this study
would likely not serve as a viable full substitute for ciga-
rettes. A caveat remains in that we only tested one brand
and there is substantial variability among marketed prod-
ucts in terms of quality and nicotine delivery [2,8]. More-
over, this finding may not generalize across the product
class. Indeed, emerging data and product evolution sug-
gest that newer second- and third-generation devices such
as e-Go and tank systems deliver nicotine in larger doses
and are preferred by experienced vapers [32].
Limitations within this study make replication neces-
sary. Only 38 participants initiated the study, less thanhalf of whom were compliant in abstaining from regular
cigarettes for the 72 hour duration. Further, we had
intended to complete a more in-depth analysis of topog-
raphy from the laboratory and home measurements for
both cigarettes and ENDS, but equipment failures and
noncompliance led to significant data loss that reduced
power to detect effects. There were too few compliant par-
ticipants with viable data to perform analyses of the final
visit. Lastly, investigation of the puffing behavior and re-
sponses of smokers using an ENDS that matches the nico-
tine levels generated by the conventional comparator
(own brand tobacco cigarettes) is of great interest. Here,
the “Smoke 51 TRIO” was an entry level three-piece
model with insufficient nicotine delivery. Participants were
instructed to abstain from smoking their normal cigarette
for 72 hours and only use the ENDS provided. The test of
compliance was a CO reading of ≤8 ppm. Because CO
levels in smokers can return to non-smoking levels within
24 hours of abstinence, one may hypothesize that partici-
pants could attempt to “cheat the system” by smoking
their regular cigarettes for the first 48 hours and abstain-
ing for the final 24, or vice versa. However, the clearance
rate of CO was not explained to the participants. Add-
itionally, the participants deemed compliant by the CO
measurement reported the greatest decrease in cigarette
use and increase in ENDS use over the 72 hour period.
Thus, in this case, we believe that CO did provide a rela-
tively reliable measure of compliance.
In April 2014, the FDA issued a proposed rule deeming
e-cigarettes as tobacco products subject to the Tobacco
Control Act [33]. Accumulation of data from studies seek-
ing to understand how consumers use ENDS can only
serve to clarify their potential public health risks and
benefits.Conclusions
Overall, upon initial use, ENDS were smoked more inten-
sively than own brand cigarettes in the laboratory setting.
However, ENDS delivered significantly less nicotine, thus
participants reported them less satisfying. These findings
have implications for the viability of certain first gener-
ation ENDS as alternatives to cigarettes. Further research
should highlight newer versions of ENDS use over a lon-
ger period of time to assess their potential as substitutes
for cigarettes.Abbreviations
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